The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Santo Domingo, DR — Nineteen tests were positive for the virus in respiratory samples analyzed by the Dr. Defilló National ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

New research uses bird droppings to track avian flu in remote regions, revealing hidden hotspots and potential for early ...

Two geese found dead on the University of Massachusetts Amherst campus have tested positive for avian influenza, the university confirmed.

Highly pathogenic avian influenza is having a deadly effect on Michigan’s eagle population. A 2022 outbreak reduced breeding pairs. Now cases are going up again, and researchers are watching for a ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...

Moderna’s latest flu vaccine, based on similar mRNA technology integrated in its COVID-19 shot, displayed optimistic outcomes ...

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at ...